1 / 36

DENGUE FEVER

DENGUE FEVER. Prof. Dr. Muhammad Ali Khan MBBS, DCH, MRCP (UK) Secretary DEAG Punjab Ex Head Department of Pediatrics SIMS/Services Hospital Lahore. Dengue Virus. Family : Flaviviridae Genus : Flavivirus Serotypes : DV1, DV2, DV3, DV4 Enveloped virus 3 major proteins

Download Presentation

DENGUE FEVER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. DENGUE FEVER Prof. Dr. Muhammad Ali Khan MBBS, DCH, MRCP (UK) Secretary DEAG Punjab Ex Head Department of Pediatrics SIMS/Services Hospital Lahore

  2. Dengue Virus Family : Flaviviridae Genus : Flavivirus Serotypes : DV1, DV2, DV3, DV4 Enveloped virus 3 major proteins SS positive sense RNA Dr. S Guanasena

  3. Viral Serotypes DV1 DV2 DV3 DV4 Subgroups and clades One or more virus types in circulation during an epidemic

  4. Spectrum of Disease

  5. Clinical course of Dengue

  6. Dengue Infection Clinically significant Dengue infection may be 1. Simple dengue fever (DF) 2. Dengue hemorrhagic fever (DHF) (plasma leak <5%) 3. Dengue Shock Syndrome (DSS) (plasma leak >5%)

  7. Clinical Features – DF • Fever > 2 and < 10 days (essential criterion) • Headache • Retro orbital pain • Myalgia • Arthralgia/ severe backache/ bone pains • Rash • Bleeding manifestations (epistaxis, hematemesis, bloody stools, menorrhagia, hemoptysis) • Abdominal pain • Decreased urinary output despite adequate fluid intake • Irritability in infants

  8. DHF or DLF

  9. SHOCK A complex clinical syndrome of decreased blood flow to body tissues resulting in cellular dysfunction and eventual organ failure

  10. Plasma leaks - Pathophysiology • Host response • Subsequent infection • Previous IgG • Neutralizing (protective) • non neutralizing (replication enhancing) • Increased viremia increased TNF, interferon, interleukin-2 and hypocomplementemia endothelial injury and increased leakage • Viral response

  11. Pathophysiology of DHF • Increased capillary permeability • Protein rich fluid exudes into the interstitial space - Pleural effusion , Ascites etc. • Circulatory volume collapses – SHOCK • Sympathetic over activity • Vasoconstriction, tachycardia • Loss of volume • Reduces pulse pressure • Blood becomes thick due to loss of fluid • Rising hematocrit and delayed capillary filling • Compromised renal and hepatic perfusion – • Reduced urine output and tender hepatomegaly

  12. Patho-physiology of DHF Management of DHF during the critical stage is that of Shock But there is one important consideration: Fluid is not being lost out but it is going to 3rd space and will be resorbed back so Over-enthusiastic fluid replacement during the critical phase – when the fluid is oozing out - would result in fluid over load during the recovery phase

  13. Patho-physiology of DHF • Peopledo not die of hemorrhage in DHF • They die • Either due toshock and 20 organ failure • Or due to Pulmonary edema & fluid over loadduring the recovery phase

  14. End organ failure in DHF Approximate outcomes Single organ failure - mortality = 40% Two organ Failure - mortality = 80% Three organ failure - mortality = >99%

  15. Case review ( of 9 deaths at Services Hospital ) 8 died of profound shockand associated end organ failure Only one had suspected CVA as a cause of death

  16. Clinical course of DHF Course of simple Dengue fever is generally uneventful and non-fatal Whereas DHF can be life-threatening Differentiating DF from DHF is critical

  17. Clinical course of DHF • Both the DF and DHFcan have bleeding tendencies therefore: Bleeding is not the differentiating point between the two

  18. Clinical course of DHF Clinical course can be divided into three stages Febrile Phase Critical Phase Recovery Phase

  19. Clinical course of DHF Febrile Phase High fever Some petechial hemorrhages With generalized aches & pains and headache; this usually lasts two to seven days People generally don’t die during this stage

  20. Clinical course of DHF Critical Phase Starts with the resolution of fever Occurs in a few people Lasts for just 24-48 hours or so Is associated with plasma leak – volume depletion & shock This is the phase where management is critical

  21. Clinical course of DHF DHF is classically associated with Plasma leakinto the 3rd compartment And circulatory compromise

  22. Signs of plasma leak in DHF Patient is not feeling well with resolution of fever Warning signs Low pulse pressure <20 mm Low urine output Delayed capillary filling Tender hepatomegaly

  23. Signs of impending DHF Warning signs (lab reports) Increasing hematocrit Edema of the gall bladder, ascites or pleural effusion Low albumin Low cholesterol Acute fall in platelet count

  24. Rate of Fluid loss and intake (Critical Phase)

  25. Clinical course of DHF Recovery Phase Volume gets resorbed Volume over-load may occur This is the phase where people die because of the problems faced during the critical stage

  26. Lab Diagnosis

  27. IgG antibody - specific to the initial infecting DV serotype + cross reacting antibody IgM antibody to the secondary infecting DV serotype Following primary infection – Specific antibody response + CMI (memory T cells) Cross reactive antibody response + CMI (memory T cells) Dr. S Guanasena

  28. Investigations • CBC and platelet count • First 5 days • NS 1 • PCR • >5 days • IgM • IgG

  29. Update on vaccine • Chimera vaccine • Yellow fever & dengue • Launched 2016 • Partial immunity • Risk of secondary infection • Attenuated vaccine • 6-8 cycles in DKC (Dog kidney cells)

  30. HAVE WE DONE ENOUGH? Asia pacific strategic plan for control of Dengue (2010-2015) What are our Goals????? • Decrease prevalence by 10% per year • Keep DHF mortality below 1%

  31. Current situation in Punjab Lahore2011 Rawalpindi2015 DEN 1,2,3,4 2349 cases (uptill 27-10-2015) > 300 cases of DHF and DSS 10 deaths • DEN 2 • Innumerable • Few DHF DEAG TRINED MEDICS AND PARAMEDICS = 13000

  32. Current situation in Punjab Lahore, 2016 Rawalpindi, 2016 DEN 1,2,3 299 18 03 deaths • DEN 1 • 109 • Few DHF • No death DEAG TRINED MEDICS AND PARAMEDICS = 3165

  33. Take Home message We can prevent quite a few deaths ---- if we can Differentiate DF from DHF Diagnose the onset of critical phase (phase of leaking) Give appropriate fluids

  34. Thank you

More Related